NYSEAMERICAN:ARMP

Armata Pharmaceuticals Stock Forecast, Price & News

$5.59

-0.16 (-2.78 %)

(As of 02/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.55

Now: $5.59▼

$5.79

50-Day Range

$2.65

MA: $2.87▼

$3.12

52-Week Range

$2.52

Now: $5.59▼

$10.48

Volume27,325 shs

Average Volume66,774 shs

Market Capitalization$104.54 million

P/E RatioN/A

Dividend YieldN/A

Beta1.74

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.

Headlines

Armata Pharmaceuticals Announces $20M Investment to Support Advancement of the Company's Bacteriophage Development Programs
January 29, 2021 | benzinga.com

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
January 27, 2021 | finance.yahoo.com

Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
December 9, 2020 | finance.yahoo.com

Rainbows and Unicorns: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Analysts Just Became A Lot More Optimistic
November 17, 2020 | nasdaq.com

Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts
November 17, 2020 | finance.yahoo.com

Earnings Update: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Just Reported And Analysts Are Boosting Their Estimates
November 15, 2020 | nasdaq.com

Earnings Beat: Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
November 15, 2020 | finance.yahoo.com

Armata Pharmaceuticals EPS misses by $0.06, misses on revenue
November 12, 2020 | seekingalpha.com

Armata Pharmaceuticals Announces Third Quarter 2020 Results and Provides General Corporate Update
November 12, 2020 | finance.yahoo.com

Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development
October 26, 2020 | finance.yahoo.com

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections
October 21, 2020 | finance.yahoo.com

Armata Pharma on go with mid-stage study of AP-PA02 in pseudomonas aeruginosa infections
October 15, 2020 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:ARMP

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.armatapharma.com

Phone(310) 655-2928

Employees33

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio2.41

Quick Ratio2.41

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.47 per share

Price / Book3.80

Profitability

EPS (Most Recent Fiscal Year)($2.55)

Net Income$-19,480,000.00

Net MarginsN/A

Return on Equity-78.74%

Return on Assets-48.92%

Miscellaneous

Outstanding Shares18,702,000

Market Cap$104.54 million

Next Earnings Date3/18/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.66 out of 5 stars

Medical Sector

288th out of 1,962 stocks

Biological Products, Except Diagnostic Industry

33rd out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Armata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.33, Armata Pharmaceuticals has a forecasted upside of 31.2% from its current price of $5.59.
Amount of Analyst Coverage
Armata Pharmaceuticals has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
Armata Pharmaceuticals has received 35 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Armata Pharmaceuticals has received 35 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Armata Pharmaceuticals has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Armata Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Armata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Armata Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
65.30% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.68% of the stock of Armata Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Armata Pharmaceuticals are expected to grow in the coming year, from ($1.28) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Armata Pharmaceuticals is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Armata Pharmaceuticals is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Armata Pharmaceuticals has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$5.59

-0.16 (-2.78 %)

(As of 02/26/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ARMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions

Is Armata Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Armata Pharmaceuticals stock.
View analyst ratings for Armata Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Armata Pharmaceuticals?

Wall Street analysts have given Armata Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Armata Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a decline in short interest in February. As of February 12th, there was short interest totaling 55,700 shares, a decline of 44.1% from the January 28th total of 99,600 shares. Based on an average trading volume of 51,400 shares, the short-interest ratio is currently 1.1 days.
View Armata Pharmaceuticals' Short Interest.

When is Armata Pharmaceuticals' next earnings date?

Armata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Armata Pharmaceuticals.

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals Inc. (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.11. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $1.75 million.
View Armata Pharmaceuticals' earnings history.

What price target have analysts set for ARMP?

4 Wall Street analysts have issued 1 year price objectives for Armata Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Armata Pharmaceuticals' share price to reach $7.33 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for Armata Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Armata Pharmaceuticals' key executives?

Armata Pharmaceuticals' management team includes the following people:

Mr. Todd R. Patrick, CEO & Director (Age 58, Pay $556.2k)
Dr. Brian Varnum, Pres & Chief Devel. Officer (Age 61, Pay $409.6k)
Mr. Steven R. Martin, Sr. VP & CFO (Age 60, Pay $409.6k)
Dr. Wenyuan Shi, Co-Founder & Founding Scientist
Mr. Duane Alfred Morris B.A., BA, VP of Operations (Age 71)

Who are some of Armata Pharmaceuticals' key competitors?

Some companies that are related to Armata Pharmaceuticals include AVROBIO (AVRO), Opthea (OPT), Freeline Therapeutics (FRLN), Cellular Biomedicine Group (CBMG), Outlook Therapeutics (OTLK), SQZ Biotechnologies (SQZ), Cardiff Oncology (CRDF), Innate Pharma (IPHA), Codiak BioSciences (CDAK), Aptose Biosciences (APTO), Innate Pharma (IPHYF), Lineage Cell Therapeutics (LCTX), Surface Oncology (SURF), Autolus Therapeutics (AUTL) and Eiger BioPharmaceuticals (EIGR).
View all of ARMP's competitors.

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), (ALT), CRISPR Therapeutics (CRSP), Pfizer (PFE), Micron Technology (MU), Aduro Biotech (ADRO), Occidental Petroleum (OXY) and Gilead Sciences (GILD).

What is Armata Pharmaceuticals' stock symbol?

Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.53%) and BlackRock Inc. (0.19%).
View institutional ownership trends for Armata Pharmaceuticals.

Which institutional investors are selling Armata Pharmaceuticals stock?

ARMP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Armata Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Armata Pharmaceuticals stock?

ARMP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Armata Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Armata Pharmaceuticals' stock price today?

One share of ARMP stock can currently be purchased for approximately $5.59.

How much money does Armata Pharmaceuticals make?

Armata Pharmaceuticals has a market capitalization of $104.54 million. The company earns $-19,480,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Armata Pharmaceuticals have?

Armata Pharmaceuticals employs 33 workers across the globe.

What is Armata Pharmaceuticals' official website?

The official website for Armata Pharmaceuticals is www.armatapharma.com.

Where are Armata Pharmaceuticals' headquarters?

Armata Pharmaceuticals is headquartered at 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292.

How can I contact Armata Pharmaceuticals?

Armata Pharmaceuticals' mailing address is 4503 GLENCOE AVENUE, MARINA DEL REY CA, 90292. The company can be reached via phone at (310) 655-2928 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here